Skip to main content

clinical_trial_update

Lundbeck Presents Bexicaserin Dual-Action Data at Epilepsy Congress

Valby, Denmark – September 07, 2026 -- Lundbeck will present preclinical data at the European Epilepsy Congress in Athens showing its investigational drug bexicaserin simultaneously increases inhibitory and decreases excitatory neuronal activity in hippocampal brain tissue, a dual mechanism the company says supports broad-spectrum antiseizure potential across multiple epilepsy types.

Preclinical study links dual mode of action to broader seizure control
The data, to be shown in an oral presentation at the September 5-9 congress, indicate bexicaserin's effects in preclinical models span focal, generalized motor and absence seizures across different underlying etiologies. Researchers attribute the effects to the compound's high affinity and selectivity for the 5-HT2C receptor, where it acts as a superagonist.

Veloxis Doses First Patient in Phase 2 Kidney Transplant Drug Trial

Veloxis Doses First Patient in Phase 2 Kidney Transplant Drug Trial

CARY, N.C. -- September 01, 2026 -- Veloxis Pharmaceuticals dosed the first participant on Aug. 31, 2026, in its Phase 2 RENGEVITY-201 trial testing pegrizeprument, an investigational immunosuppressive drug, against tacrolimus in kidney transplant recipients. The Cary, North Carolina-based company, a unit of Asahi Kasei Corporation, will enroll up to 120 de novo kidney transplant patients across multiple sites in the randomized, partially blinded study registered as NCT07290777. Patients will receive one of two pegrizeprument doses or tacrolimus, each layered on top of rATG, corticosteroids and mycophenolate maintenance therapy.